ROE của cổ phiếu STRO là bao nhiêu?

SUTRO BIOPHARMA có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 229.64%.

Tỷ suất cổ tức của STRO là bao nhiêu?

SUTRO BIOPHARMA có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của STRO là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của STRO ở mức 54/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu STRO không?

Điểm AI Timing của STRO là 27/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu STRO thuộc ngành nào?

SUTRO BIOPHARMA được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu STRO (NASDAQ) | SUTRO BIOPHARMA

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

STRO AI Analysis Summary

Our AI summary for STRO: SUTRO BIOPHARMA (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 229.64%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

STRO

SUTRO BIOPHARMA

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 24.17

-0.65 (-2.62%) Day Change

Watchlist Portfolio Compare Chart

-0.11

D/E

229.6%

ROE

-63.5%

ROA

0.00%

Div Yield

SUTRO BIOPHARMA
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 24.17 Price -0.65 (-2.62%) Day Change	NEWS SCORE: N/A

STRO Chất lượng tổng thể của cố phiếu Không tốt lắm ( Chất lượng = 54) và Thời điểm mua ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	24.17
PBV / Sector	-6.15 / 5.20
Earning Per Share	-9.03

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	7.99 M
Average 1W Daily Value	4.62 M GREAT

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-154.21 / 98.71
NPM Average (%) / Sector	-190.53 / -1,721.76
NPM Change Average (%) / Sector	75.20 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-63.48 / 27.02
ROA Average (%) / Sector	-56.83 / -368.17
ROA Change Average (%) / Sector	45.31 / 5,404.12 GREAT
ROE (%) / Sector	229.64 / 3.47 GREAT
ROE Average (%) / Sector	-52.47 / 6.51
ROE Change Average (%) / Sector	143.87 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:32
Symbol	STRO
Name	SUTRO BIOPHARMA
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	16.57 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	411.28 / 9,903.94

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Phone: 650 881 6500

Website: https://www.sutrobio.com

Employees: 133

Sector: Healthcare >> Biotechnology

Description: Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.